

TIA1 Polyclonal Antibody

Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP58597

Product Information

Application	IHC-P, IHC-F, IF, E
Primary Accession	P31483
Reactivity	Rat, Pig, Dog
Host	Rabbit
Clonality	Polyclonal
Calculated MW	42963
Physical State	Liquid
Immunogen	KLH conjugated synthetic peptide derived from human TIA1
Epitope Specificity	101-200/386
Purity	affinity purified by Protein A
Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
SUBCELLULAR LOCATION	Cytoplasmic granule. Nucleus. Note=Accumulates in cytoplasmic stress granules (SG) following cellular damage.
SIMILARITY	Contains 3 RRM (RNA recognition motif) domains.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background Descriptions	Involved in alternative pre-RNA splicing and regulation of mRNA translation by binding to AU-rich elements (AREs) located in mRNA 3' untranslated regions (3' UTRs). Possesses nucleolytic activity against cytotoxic lymphocyte target cells. May be involved in apoptosis.

Additional Information

Gene ID	7072
Other Names	Nucleolysin TIA-1 isoform p40, RNA-binding protein TIA-1, T-cell-restricted intracellular antigen-1, TIA-1, p40-TIA-1, TIA1
Dilution	IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000
Format	0.01M TBS(pH7.4) with 1% BSA, 0.09% (W/V) sodium azide and 50% Glyce
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Protein Information


Name	TIA1
-------------	------

Function	<p>RNA-binding protein involved in the regulation of alternative pre-RNA splicing and mRNA translation by binding to uridine-rich (U- rich) RNA sequences (PubMed:11106748, PubMed:12486009, PubMed:17488725, PubMed:8576255). Binds to U-rich sequences immediately downstream from a 5' splice sites in a uridine-rich small nuclear ribonucleoprotein (U snRNP)-dependent fashion, thereby modulating alternative pre-RNA splicing (PubMed:11106748, PubMed:8576255). Preferably binds to the U- rich IAS1 sequence in a U1 snRNP-dependent manner; this binding is optimal if a 5' splice site is adjacent to IAS1 (By similarity). Activates the use of heterologous 5' splice sites; the activation depends on the intron sequence downstream from the 5' splice site, with a preference for a downstream U-rich sequence (PubMed:11106748). By interacting with SNRPC/U1-C, promotes recruitment and binding of spliceosomal U1 snRNP to 5' splice sites followed by U-rich sequences, thereby facilitating atypical 5' splice site recognition by U1 snRNP (PubMed:11106748, PubMed:12486009, PubMed:17488725). Activates splicing of alternative exons with weak 5' splice sites followed by a U-rich stretch on its own pre-mRNA and on TIAR mRNA (By similarity). Acts as a modulator of alternative splicing for the apoptotic FAS receptor, thereby promoting apoptosis (PubMed:11106748, PubMed:17488725, PubMed:1934064). Binds to the 5' splice site region of FAS intron 5 to promote accumulation of transcripts that include exon 6 at the expense of transcripts in which exon 6 is skipped, thereby leading to the transcription of a membrane-bound apoptotic FAS receptor, which promotes apoptosis (PubMed:11106748, PubMed:17488725, PubMed:1934064). Binds to a conserved AU-rich cis element in COL2A1 intron 2 and modulates alternative splicing of COL2A1 exon 2 (PubMed:17580305). Also binds to the equivalent AT-rich element in COL2A1 genomic DNA, and may thereby be involved in the regulation of transcription (PubMed:17580305). Binds specifically to a polypyrimidine-rich controlling element (PCE) located between the weak 5' splice site and the intronic splicing silencer of CFTR mRNA to promote exon 9 inclusion, thereby antagonizing PTB1 and its role in exon skipping of CFTR exon 9 (PubMed:14966131). Involved in the repression of mRNA translation by binding to AU-rich elements (AREs) located in mRNA 3' untranslated regions (3' UTRs), including target ARE-bearing mRNAs encoding TNF and PTGS2 (By similarity). Also participates in the cellular response to environmental stress, by acting downstream of the stress-induced phosphorylation of EIF2S1/EIF2A to promote the recruitment of untranslated mRNAs to cytoplasmic stress granules (SGs), leading to stress-induced translational arrest (PubMed:10613902). Formation and recruitment to SGs is regulated by Zn(2+) (By similarity). Possesses nucleolytic activity against cytotoxic lymphocyte target cells (PubMed:1934064).</p>
Cellular Location	<p>Nucleus. Cytoplasm Cytoplasm, Stress granule Note=Accumulates in cytoplasmic stress granules (SG) following cellular damage (PubMed:10613902, PubMed:15371533). Recruitment to SG is induced by Zn(2+) (By similarity). {ECO:0000250 UniProtKB:P52912, ECO:0000269 PubMed:10613902, ECO:0000269 PubMed:15371533}</p>
Tissue Location	<p>Expressed in heart, small intestine, kidney, liver, lung, skeletal muscle, testes, pancreas, and ovary (at protein level)</p>


Images

Tissue/cell: rat uterus; 4% Paraformaldehyde-fixed and paraffin-embedded;

Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal



goat serum,C-0005) at 37°C for 20 min;
 Incubation: Anti-TIA1 Polyclonal Antibody,
 Unconjugated(AP58597) 1:500, overnight at 4°C, followed
 by conjugation to the secondary antibody(SP-0023) and
 DAB(C-0010) staining



Tissue/cell: human colon carcinoma; 4%
 Paraformaldehyde-fixed and paraffin-embedded;
 Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling
 bathing for 15min; Block endogenous peroxidase by 3%
 Hydrogen peroxide for 30min; Blocking buffer (normal
 goat serum,C-0005) at 37°C for 20 min;
 Incubation: Anti-TIA1 Polyclonal Antibody,
 Unconjugated(AP58597) 1:500, overnight at 4°C, followed
 by conjugation to the secondary antibody(SP-0023) and
 DAB(C-0010) staining

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.